Jade Biosciences
JBIO
58 hedge funds and large institutions have $386M invested in Jade Biosciences in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 3 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.01% less ownership
Funds ownership: 2.95% → 2.94% (-0.01%)
2% less funds holding
Funds holding: 59 → 58 (-1)
21% less capital invested
Capital invested by funds: $488M → $386M (-$102M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.01M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.07M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$1.92M |
| 4 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$717K |
| 5 |
FAM
Fred Alger Management
New York
|
-$513K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
51
STRS Ohio
Columbus,
Ohio
| $31K | – | – | – |
|
52
Wells Fargo
San Francisco,
California
| $30.6K | -$30.3K | -56 | -47% |
|
|
AB
53
Amalgamated Bank
New York
| $21K | – | – | – |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| $19.5K | +$8.12K | +15 | +58% |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| $19K | +$8.12K | +15 | +60% |
|
|
AIP
56
Ameritas Investment Partners
Lincoln,
Nebraska
| $10.5K | – | – | – |
|
|
MLICM
57
Metropolitan Life Insurance Company (MetLife)
New York
| $9.51K | – | – | – |
|
58
Citigroup
New York
| $2.89K | -$48.2K | -89 | -94% |
|
|
59
Citadel Advisors
Miami,
Florida
| – | -$5.01M | -8,341 | Closed |
|
|
HS
60
HighVista Strategies
Boston,
Massachusetts
| – | -$717K | -1,194 | Closed |
|
61
Russell Investments Group
London,
United Kingdom
| – | -$16.1K | -27 | Closed |
|
62
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$120 | – | – |
|
JBIO Hedge Fund Activity: Q3 2023 in Review
58 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q3 2023, worth a combined $386M — down 21% from $488M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of JBIO and 2 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 22 added.
The largest buyer was Frazier Life Sciences Management, adding an estimated $3.25M. The largest seller was Citadel Advisors, exiting entirely with an estimated $5.01M sold.
- 58 institutional investors held Jade Biosciences (JBIO) as of Q3 2023, down from 59 in Q2 2023.
- Funds reported $386M of Jade Biosciences stock for Q3 2023, down 21% quarter-over-quarter.
- 2 funds opened new Jade Biosciences positions in Q3 2023 and 3 closed out, a net change of -1 holder.
- The largest Jade Biosciences buyer in Q3 2023 was Frazier Life Sciences Management, an estimated $3.25M added.
- The largest Jade Biosciences seller in Q3 2023 was Citadel Advisors, an estimated $5.01M sold.
Based on aggregated 13F filings for Q3 2023.